Castle Biosciences' Cost of Revenue rose 1982.83% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.9 million, marking a year-over-year increase of 2205.86%. This contributed to the annual value of $60.2 million for FY2024, which is 3384.24% up from last year.
Castle Biosciences' Cost of Revenue amounted to $18.7 million in Q3 2025, which was up 1982.83% from $17.6 million recorded in Q2 2025.
In the past 5 years, Castle Biosciences' Cost of Revenue registered a high of $18.7 million during Q3 2025, and its lowest value of $3.0 million during Q1 2021.
Its 5-year average for Cost of Revenue is $10.8 million, with a median of $11.1 million in 2023.
As far as peak fluctuations go, Castle Biosciences' Cost of Revenue skyrocketed by 10789.83% in 2022, and later surged by 1791.42% in 2025.
Castle Biosciences' Cost of Revenue (Quarter) stood at $4.6 million in 2021, then surged by 107.09% to $9.5 million in 2022, then surged by 30.49% to $12.4 million in 2023, then skyrocketed by 30.27% to $16.2 million in 2024, then rose by 15.58% to $18.7 million in 2025.
Its last three reported values are $18.7 million in Q3 2025, $17.6 million for Q2 2025, and $16.4 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value